The key COVID-19 findings in allergy, distilled into a clear, readable brief. The evidence is here whenever you want to go deeper.
INSIDE THIS MONITOR
30cited sources
2available findings
Study findings updated
AI-assisted evidence summary. For general information. These findings are not individual medical advice or a clinician endorsement.
THE SHORT VERSION
What’s worth knowing.
The key findings, what they mean, and the context that matters.
THE HEADLINE TAKEAWAY20-40%
Histamine intolerance was reported among Long COVID patients
A prevalence of 20-40% was reported for histamine intolerance among Long COVID patients.
The study design and timeframe are not recorded. The diagnostic definition and sampling method are not available in this summary.
See the evidence
Histamine Intolerance
20-40% Prevalence in Long COVID patients
Comas-Baste O, Sanchez-Perez S, Veciana-Nogues MT, Latorre-Moratalla M, Vidal-Carou MDC. Histamine Intolerance: The Current State of the Art. Biomolecules. 2020;10(8):1181.
Study-specific findings. Different populations, treatments and follow-up periods can produce different results.
THE RESEARCH, AS IT ARRIVES
Latest studies.
The newest findings added to this collection. The learning from each, already distilled.
Study summaries are not available in this collection yet. The original evidence remains accessible in each monitor.
Dates show when findings were added here, not when papers were published. Study populations and comparisons differ.
WHEN YOU WANT TO GO DEEPERSee all 2 findingsOriginal results, comparisons and study details.
2 of 2 source groupsFindings stay together with their study.
SOURCE 061 finding
Comas-Baste O, Sanchez-Perez S, Veciana-Nogues MT, Latorre-Moratalla M, Vidal-Carou MDC. Histamine Intolerance: The Current State of the Art. Biomolecules. 2020;10(8):1181.
Afrin LB, Weinstock LB, Molderings GJ. COVID-19 hyperinflammation and post-COVID-19 illness may be rooted in mast cell activation syndrome. Int J Infect Dis. 2020;100:327-332.
Theoharides TC, Conti P. COVID-19 and multisystem inflammatory syndrome, or is it mast cell activation syndrome? J Biol Regul Homeost Agents. 2020;34(5):1633-1636.
Original source link unavailable
[4]
Kolkhir P, Gimenez-Arnau AM, Kulthanan K, Peter J, Metz M, Maurer M. Urticaria. Nat Rev Dis Primers. 2022;8(1):61.
Leru PM, Anton VF, Ghinghina G, Bocsan IC, Buzoianu AD. Mast cell activation syndromes - evaluation of current diagnostic criteria and laboratory tools in clinical practice. Front Allergy. 2023;4:1257441.
Original source link unavailable
[6]
Comas-Baste O, Sanchez-Perez S, Veciana-Nogues MT, Latorre-Moratalla M, Vidal-Carou MDC. Histamine Intolerance: The Current State of the Art. Biomolecules. 2020;10(8):1181.
Original source link unavailable
[7]
Maintz L, Novak N. Histamine and histamine intolerance. Am J Clin Nutr. 2007;85(5):1185-1196.
Original source link unavailable
[8]
Molderings GJ, Brettner S, Homann J, Afrin LB. Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. J Hematol Oncol. 2011;4:10.
Original source link unavailable
[9]
Patel P, DeCuir J, Engmann J, et al. Post-COVID-19 Condition: A Systematic Review of Immunological Mechanisms. Clin Immunol. 2024;258:109852.
Original source link unavailable
[10]
Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell. 2020;181(5):1036-1045.e9.
Original source link unavailable
[11]
Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med. 2012;18(5):693-704.
Original source link unavailable
[12]
Maurer M, Rosen K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368(10):924-935.
Original source link unavailable
[13]
Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. 2022;28(7):1461-1467.
Original source link unavailable
[14]
Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28(3):583-590.
Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nat Med. 2022;28(11):2398-2405.
Original source link unavailable
[16]
Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626-631.
Original source link unavailable
[17]
Valent P, Akin C, Bonadonna P, et al. Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome. J Allergy Clin Immunol Pract. 2019;7(4):1125-1133.e1.
Original source link unavailable
[18]
Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA(2)LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734-766.
Original source link unavailable
[19]
Castells MC, Phillips EJ. Maintaining Safety with SARS-CoV-2 Vaccines. N Engl J Med. 2021;384(7):643-649.
Original source link unavailable
[20]
Centers for Disease Control and Prevention. COVID-19 Vaccines and Allergic Reactions. Updated 2024.
Original source link unavailable
[21]
Tan M, Liu Y, Zhou R, et al. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China. Immunology. 2020;160(3):261-268.
Original source link unavailable
[22]
Carvelli J, Demaria O, Vely F, et al. Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis. Nature. 2020;588(7836):146-150.
Original source link unavailable
[23]
Motta Junior JDS, Miggiolaro AFRDS, Nagashima S, et al. Mast Cells in Alveolar Septa of COVID-19 Patients: A Pathogenic Pathway That May Link Interstitial Edema to Immunothrombosis. Front Immunol. 2020;11:574862.
Original source link unavailable
[24]
Lyons JJ, Yu X, Hughes JD, et al. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet. 2016;48(12):1564-1569.
Original source link unavailable
[25]
Hamilton MJ, Hornick JL, Akin C, Castells MC, Greenberger NJ. Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations. J Allergy Clin Immunol. 2011;128(1):147-152.e2.
Original source link unavailable
[26]
Khoury P, Lyons JJ. Mast cell activation in the context of elevated basal serum tryptase: genetics and presentations. Curr Allergy Asthma Rep. 2019;19(12):55.
Hartmann K, Escribano L, Grattan C, et al. Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis. J Allergy Clin Immunol. 2016;137(1):35-45.
Original source link unavailable
[29]
Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133-146.
Original source link unavailable
[30]
Proal AD, VanElzakker MB. Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms. Front Microbiol. 2021;12:698169.
Original source link unavailable
ABOUT THIS MONITOR
Understanding includes the limits.
This is an AI-assisted evidence summary, not a clinician endorsement. Read each original paper for its complete methods, population and limitations. Different studies can ask different questions and report different kinds of results.
Dates marked “added” describe when a finding entered this monitor, not when the study was published or clinically reviewed. Personal health and treatment decisions belong in a conversation with a qualified clinician.